SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as investors rally behind its community-driven, grassroots growth and active engagement on social platforms while awaiting the debut of its official chart. The community is actively discussing accumulation opportunities and potential price milestones, emphasizing a long-term 'diamond hand' strategy to distinguish the token from typical short-lived meme coin pumps.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch is trending as the community highlights its model of distributing Solana rewards to holders every six hours, positioning the token as a passive income play. Despite polarized debates regarding price performance and risks of retracement, bulls are actively focused on the project's long-term utility and recent infrastructure updates.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot (DRB) is currently trending as community members rally around its unique connection to Grok-based AI, with participants emphasizing its potential for significant growth during the current bull cycle. Investors are actively discussing the token's low follower count and early market stage, drawing parallels to established meme coins while highlighting its strategic integration within the broader Base ecosystem.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is currently capturing community attention as a legacy meme project that draws parallels to Bitcoin's early skeptical reception while positioning itself as a satirical store of value. Investors are actively debating its potential for long-term growth, with proponents emphasizing the project's historical roots and its narrative as a community-driven movement that aims to challenge conventional financial norms.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining strong momentum driven by anticipation surrounding its upcoming cross-chain expansion and a strategic merger, with the community closely tracking its role as the central liquidity hub within the Base ecosystem. Investors are highlighting its robust fee generation and active supply reduction models as key indicators of long-term utility, fueling bullish sentiment despite recent market volatility.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is surging alongside the broader crypto market following news of a two-week ceasefire between the U.S. and Iran, which has sparked optimism over the stabilization of global trade and energy supply lines. The community is actively discussing the potential for a sustained breakout, with many traders closely monitoring institutional inflows and technical resistance levels to determine if the rally can maintain momentum.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Arbitrum is currently capturing significant attention as the crypto community debates the tension between its strong fundamental position as a leading Ethereum Layer 2 and ongoing price pressure from token unlocks. Traders are actively discussing the impact of institutional partnerships, such as Robinhood's use of the chain for tokenized assets, while balancing long-term bullish sentiment against near-term selling pressure.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently facing intense community debate regarding its lack of significant price action compared to the broader market, with many participants actively discussing potential upcoming business developments and strategic news anticipated for 2026. While some investors remain committed to long-term accumulation, others are voicing frustration over prolonged stagnation and the project's perceived lag behind Bitcoin and emerging niche tokens.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is seeing significant market activity as investors weigh the long-term impact of GLP-1 weight-loss drugs on the dialysis sector, leading to heightened volatility and concerns about future patient growth. The community is actively debating whether the recent sell-off represents an overreaction to medical trial news or a fundamental shift in the kidney care landscape that warrants a defensive posture.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a community-driven project that aims to bridge global cannabis culture with Web3, attracting long-term holders focused on organic growth and advocacy. Investors are actively discussing its potential ahead of upcoming cannabis-related milestones, while sentiment remains centered on the token's identity as a 'culture-first' alternative to traditional speculative memes.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HCW Biologics Secures $7M Licensing Deal for Promising Immunotherapy

HCW Biologics (NASDAQ:HCWB) finalized an exclusive worldwide licensing agreement for its fusion immunotherapeutic candidate HCW11-006, marking a meaningful step in expanding its global development strategy.

Small Cap Stocks To Keep An Eye On - March 16th

CytomX Therapeutics, HCW Biologics, Direxion Daily MU Bull 2X Shares, Meiwu Technology, and AltC Acquisition are the five Small Cap stocks to watch today, according to MarketBeat's stock screener...

Promising Pharmaceutical Stocks To Keep An Eye On - March 16th

Eli Lilly and Company, CytomX Therapeutics, Pfizer, HCW Biologics, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks...

Biotech Breakthroughs and Capital Moves Drive a Busy Market Week

A wave of biotech developments, strategic financings, and emerging-technology announcements shaped market narratives this week, highlighting how innovation across biopharma, AI-driven automation, energy technology, and crypto finance continues to drive investor attention. $CTMX, $NVDA, $HCWB, $KBLB, $CYN, $BMNR, $CLIK, $CIIT, $AIRS, $DFLI

<ul class="summary-bullets"><li>HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.</li><li>The company said that CAR-Ts produced with its reagent are highly enriched in long-lived T memory stem cells.</li><li>HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.</li></ul>HCW Biologics Inc. (HCWB) shares soared more than 56% in Monday’s pre-market trade after the company announced positive research results for its CAR-T cell therapy.HCW Biologics stated that HCW9206, its proprietary, commercial-stage multi-cytokine fusion protein reagent, provides a new approach to generate CAR-T cells for immunotherapy with increased function at a cost-effective price.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/HCWB">HCW Biologics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels.<h2 class="st-heading-2">HCW9206 CAR-Ts Outperform Standard Methods, Says Company</h2>HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.The company said that CAR-Ts produced using its reagent are highly enriched in long-lived T-memory stem cells. HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.“Based on experimental models, HCW9206 has shown improvement in functional activities and persistence of CAR-Ts following adoptive transfer, a goal the industry has been trying to achieve for the last decade,” said HCW Biologics CEO, Dr. Hing C. Wong.The company stated that in its study, HCW9206 helped generate long-lasting duoCAR-T cells that showed strong HIV suppression in humanized mouse models using T cells from people living with HIV. The approach could extend CAR-T therapy durability and support efforts toward a functional HIV cure, it added.<h2 class="st-heading-2">Why Are CAR-T Cells Important?</h2>CAR-T cells represent a new way to treat cancer using the patient’s own immune system. These cells genetically modify a patient’s T cells so they can recognize and attack specific cancer cells, reducing damage to healthy tissue compared with traditional treatments.Additionally, once CAR-T cells are modified and infused into a patient’s body, they multiply and continue to fight cancer.<a href="https://stocktwits.com/symbol/HCWB">HCWB stock</a> is down 47% year-to-date and 96% over the past 12 months. The Vanguard Extended Market Index Fund ETF Shares (VXF) is up 20% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soc-stock-soars-after-sable-resumes-oil-flow-from-california-pipeline/cZ32wB1RIfi">SOC Stock Rises Pre-Market After Energy Secretary Order Restarts Sable’s California Oil Pipeline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy

HCW Biologics said its proprietary multi-cytokine fusion protein reagent, HCW9206, offers a cost-effective way to generate higher-function CAR-T cells for immunotherapy.

Equity

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7R, and Others  DelveInsight

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7R, and Others | DelveInsight Alopecia Areata Market Set to...

HCW Biologics shares logged their best session in over three months on Monday after the firm revealed progress with a new cancer drug it thinks could be a multi-billion-dollar blockbuster.The stock jumped 60.8% to $5.55 on Monday, marking its best session since May 13, before adding another 0.5% in after-hours trading.The Florida-based biotech firm said it has developed an advanced form of pembrolizumab, which is sold by Merck as Keytruda and is considered the world’s top-selling FDA-approved immune checkpoint inhibitor.Drugs in this class are designed to help the immune system fight cancer, but they often only work for a small percentage of patients, and results are not always long-lasting.HCW Biologics said its version aims to go a step further: not only releasing the “brake” on the immune system but also activating immune cells and helping them infiltrate solid tumors, such as those seen in pancreatic and ovarian cancer.&nbsp;In early lab studies and mouse models, the company states that the therapy demonstrated stronger results than Keytruda alone, at dose levels that were well tolerated.CEO Hing C. Wong noted that global sales of checkpoint inhibitors topped $40 billion in 2024, underscoring the commercial potential if effectiveness can be improved.The company also sees potential for its therapy beyond cancer. HCW Biologics said checkpoint inhibitors may help clear “senescent” cells, which are aged cells that no longer divide but drive inflammation, making them a possible tool against age-related diseases.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 538% surge in 24-hour message volume, placing it among the most trending stocks on the platform.One user noted they had already taken profits, saying they made money on $HCWB and estimated early buyers likely gained 20–30%.<stembedurl>https://stocktwits.com/Camelinvesting/message/626495258</stembedurl>Another user praised HCW Biologics’ research, suggesting that since immune checkpoint inhibitors have shown success, improving on them could be the right path forward.<stembedurl>https://stocktwits.com/everything5/message/626494404</stembedurl><a href="https://stocktwits.com/symbol/HCWB">HCW Biologics’ stock</a> has declined 68.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

HCW Biologics (HCWB) shares logged their best session in over three months on Monday after the firm revealed progress with a new cancer drug it thinks could be a multi-billion-dollar blockbuster. | Image source: Getty Images

HCW Biologics Stock Scores Biggest Gain Since May As Cancer Drug Breakthrough Fuels Blockbuster Hopes

The biotech firm said its next-generation version of Keytruda showed stronger results in early studies and could eventually expand into both cancer and age-related disease treatments.

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

Current Price	$0.3645
Prev Close	$0.3373
Open	$0.3412
Dividend Yield	0.00%
50-Day Moving Average	$0.6471
Beta	0.37
Avg. Volume	22.78M
PE Ratio	-0.03

52-Week High	$17.80
52-Week Low	$0.25
Market Capitalization	$2.45M
EPS (Annual)	-$10.63
Price to Book	0.43
Revenue Per Employee	$1,549.49

HCWB
HCW Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HCWB News

HCWBHCW Biologics Inc